Cardiometabolic risk in polycystic ovary syndrome

Katica Bajuk Studen, Marija Pfeifer, Katica Bajuk Studen, Marija Pfeifer

Abstract

Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age. Besides hyperandrogenism, oligomenorrhea and fertility issues, it is associated with a high prevalence of metabolic disorders and cardiovascular risk factors. Several genetic polymorphisms have been identified for possible associations with cardiometabolic derangements in PCOS. Different PCOS phenotypes differ significantly in their cardiometabolic risk, which worsens with severity of androgen excess. Due to methodological difficulties, longer time-scale data about cardiovascular morbidity and mortality in PCOS and about possible beneficial effects of different treatment interventions is missing leaving many issues regarding cardiovascular risk unresolved.

Keywords: PCOS; cardiometabolic risk; cardiovascular risk; hyperandrogenism; obesity.

© 2018 The authors.

References

    1. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine Reviews 2015. 36 487–525. (10.1210/er.2015-1018)
    1. McCartney CR, Marshall JC. Polycystic ovary syndrome. New England Journal of Medicine 2016. 375 54–64. (10.1056/NEJMcp1514916)
    1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 1999. 84 4006–4011. (10.1210/jcem.84.11.6148)
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004. 19 41–47.
    1. Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, pp 377–384. Eds Dunaif A, Givens HR, Haseltine FP. & Merriam G. Boston, MA, USA: Blackwell Scientific, 1992.
    1. Paterakis TS, Diamanti-Kandarakis E. Aspects of cardiometabolic risk in women with polycystic ovary syndrome. Current Obesity Reports 2014. 3 377–386. (10.1007/s13679-014-0127-6)
    1. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992. 41 1257–1266. (10.2337/diab.41.10.1257)
    1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nature Reviews Disease Primer 2016. 2 16057 (10.1038/nrdp.2016.57)
    1. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999. 22 141–146. (10.2337/diacare.22.1.141)
    1. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 1999. 84 165–169. (10.1210/jcem.84.1.5393)
    1. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. Journal of Clinical Endocrinology and Metabolism 2005. 90 3236–3242. (10.1210/jc.2004-1843)
    1. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction 2001. 16 1995–1998. (10.1093/humrep/16.9.1995)
    1. Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Current Diabates Reports 2006. 6 77–83. (10.1007/s11892-006-0056-1)
    1. Livadas S, Kollias A, Panidis D, Diamanti-Kandarakis E. Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome. European Journal of Endocrinology 2014. 171 301–309. (10.1530/EJE-13-1007)
    1. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall’Alda M, et al Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2013. 98 E628–37. (10.1210/jc.2012-3908)
    1. Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. Journal of Obstetrics and Gynaecology Research 2016. 42 837–843. (10.1111/jog.12985)
    1. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nature Reviews Endocrinology 2014. 10 293–302. (10.1038/nrendo.2014.29)
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr, et al Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009. 120 1640–1645. (10.1161/CIRCULATIONAHA.109.192644)
    1. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. & PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006. 9 48–53. (10.1210/jc.2005-1329)
    1. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005. 90 1929–1935. (10.1210/jc.2004-1045)
    1. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstetrics and Gynecology 2005. 106 131–137. (10.1097/01.AOG.0000167408.30893.6b)
    1. Álvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Archives of Internal Medicine 2006. 166 2081 (10.1001/archinte.166.19.2081)
    1. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. European Journal of Endocrinology 2006. 154 141–145. (10.1530/eje.1.02058)
    1. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2010. 16 347–363. (10.1093/humupd/dmq001)
    1. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008. 93 162–168. (10.1210/jc.2007-1834)
    1. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Human Reproduction 2003. 18 2289–2293. (10.1093/humrep/deg440)
    1. Godoy-Matos AF, Vaisman F, Pedrosa AP, Farias MLF, Mendonça LMC, Pinheiro MFMC. Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecological Endocrinology 2009. 25 793–798. (10.3109/09513590903015528)
    1. Strowitzki T, Halser B, Demant T. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome. Gynecological Endocrinology 2002. 16 45–51. (10.1080/gye.16.1.45.51)
    1. Cosar E, Üçok K, Akgün L, Koken G, Sahin FK, Arioz DT, Baş O. Body fat composition and distribution in women with polycystic ovary syndrome. Gynecological Endocrinology 2008. 24 428–432. (10.1080/09513590802234253)
    1. Liou T-H, Yang J-H, Hsieh C-H, Lee C-Y, Hsu C-S, Hsu M-I. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertility and Sterility 2009. 92 1960–1965. (10.1016/j.fertnstert.2008.09.003)
    1. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, Polson DW, Reed MJ, Franks S. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clinical Endocrinology 1990. 32 213–220. (10.1111/j.1365-2265.1990.tb00857.x)
    1. Karabulut A, Yaylali GF, Demirlenk S, Sevket O, Acun A. Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. Gynecological Endocrinology 2012. 28 111–114. (10.3109/09513590.2011.589929)
    1. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clinical Endocrinology 1992. 37 119–125. (10.1111/j.1365-2265.1992.tb02295.x)
    1. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine 2001. 111 607–613. (10.1016/S0002-9343(01)00948-2)
    1. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity Reviews 2013. 14 95–109. (10.1111/j.1467-789X.2012.01053.x)
    1. Svendsen PF, Nilas L, Norgaard K, Jensen J-EB, Madsbad S. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Human Reproduction 2008. 23 2113–2121. (10.1093/humrep/den211)
    1. Cree-Green Melanie, Rahat Haseeb, Newcomer B, Bergman B. Insulin resistance, hyperinsulinemia and mitochondria dysfunction in non-obese girls woth polycystic ovary syndrome. Journal of the Endocrine Society 2017. 1 931–944. (10.1210/js.2017-00192)
    1. Thaler MA, Seifert-Klauss V, Luppa PB. The biomarker sex hormone-binding globulin – from established applications to emerging trends in clinical medicine. Best Practice and Research: Clinical Endocrinology and Metabolism 2015. 29 749–760. (10.1016/j.beem.2015.06.005)
    1. Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, Pasternak RC, Lloyd-Jones D, Sowers MF, Torréns JI, et al Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation. 2005. 111 1242–1249. (10.1161/01.CIR.0000157697.54255.CE)
    1. Helvaci N, Karabulut E, Demir AU, Yildiz BO. Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. Endocrine Connections 2017. 6 437–445. (10.1530/EC-17-0129)
    1. Fernandez RC, Moore VM, Van Ryswyk EM, Varcoe TJ, Rodgers RJ, March WA, Moran LJ, Avery JC, McEvoy RD, Davies MJ. Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Nature and Science of Sleep 2018. 10 45–64. (10.2147/NSS.S127475)
    1. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Annals of Internal Medicine 2005. 142 187–197. (10.7326/0003-4819-142-3-200502010-00010)
    1. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. New England Journal of Medicine 2000. 342 1378–1384. (10.1056/NEJM200005113421901)
    1. Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. European Respiratory Journal 2006. 28 596–602. (10.1183/09031936.06.00107805)
    1. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. Journal of Applied Physiology 2005. 99 1998–2007. (10.1152/japplphysiol.00695.2005)
    1. Tasali E, Chapotot F, Leproult R, Whitmore H, Ehrmann DA. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2011. 96 365–374. (10.1210/jc.2010-1187)
    1. Sun Y, Huang Z-Y, Sun Q-R, Qiu L-P, Zhou T-T, Zhou G-H. CPAP therapy reduces blood pressure for patients with obstructive sleep apnoea: an update meta-analysis of randomized clinical trials. Acta Cardiologica 2016. 71 275–280. (10.1080/AC.71.3.3152087)
    1. Schwarz EI, Puhan MA, Schlatzer C, Stradling JR, Kohler M. Effect of CPAP therapy on endothelial function in obstructive sleep apnoea: a systematic review and meta-analysis. Respirology 2015. 20 889–895. (10.1111/resp.12573)
    1. Xu H, Wang Y, Guan J, Yi H, Yin S. Effect of CPAP on endothelial function in subjects with obstructive sleep apnea: a meta-analysis. Respiratory Care 2015. 60 749–755. (10.4187/respcare.03739)
    1. Chen L, Kuang J, Pei J-H, Chen HM, Chen Z, Li ZW, Yang HZ, Fu XY, Wang L, Chen ZJ, et al Continuous positive airway pressure and diabetes risk in sleep apnea patients: a systemic review and meta-analysis. European Journal of Internal Medicine 2017. 39 39–50. (10.1016/j.ejim.2016.11.010)
    1. Papadakis G, Kandaraki E, Papalou O, Vryonidou A, Diamanti-Kandarakis E. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinologica 2017. 42 340–355. (10.23736/S0391-1977.17.02609-8)
    1. Sales M, Sóter M, Candido A, Fernandes AP, Oliveira FR, Ferreira AC, Sousa MO, Ferreira CN, Gomes KB. Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome. Gynecological Endocrinology 2013. 29 936–939. (10.3109/09513590.2013.819086)
    1. Güldaş M, Altinkaya SÖ, Nergiz S, Demircan-Sezer S, Yüksel H. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome. Gynecological Endocrinology 2015. 31 536–539. (10.3109/09513590.2015.1018161)
    1. Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Martinez de Maranon A, Rios-Navarro C, Alvarez A, Gomez M, Rocha M, Hernández-Mijares A. Insulin resistance in PCOS patients enhances oxidative stress and leukocyte adhesion: role of myeloperoxidase. PLoS ONE 2016. 11 e0151960 (10.1371/journal.pone.0151960)
    1. Kumarendran B, O’Reilly MW, Manolopoulos KN, Toulis KA, Gokhale KM, Sitch AJ, Wijeyaratne CN, Coomarasamy A, Arlt W, Nirantharakumar K. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database. PLoS Medicine 2018. 15 e1002542 (10.1371/journal.pmed.1002542)
    1. Armstrong MJ, Adams LA, Canbay A, Syn W-K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014. 59 1174–1197. (10.1002/hep.26717)
    1. Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepatitis Monthly 2014. 14 e23235 (10.5812/hepatmon.23235)
    1. Vassilatou E, Vassiliadi DA, Salambasis K, Lazaridou H, Koutsomitopoulos N, Kelekis N, Kassanos D, Hadjidakis D, Dimitriadis G. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. European Journal of Endocrinology 2015. 173 739–747. (10.1530/EJE-15-0567)
    1. Romanowski MD, Parolin MB, Freitas ACT, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arquivos de Gastroenterologia 2015. 52 117–123. (10.1590/S0004-28032015000200008)
    1. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, Panidis D. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clinical Endocrinology 2008. 69 634–641. (10.1111/j.1365-2265.2008.03247.x)
    1. Pertynska-Marczewska M, Diamanti-Kandarakis E, Zhang J, Merhi Z. Advanced glycation end products: a link between metabolic and endothelial dysfunction in polycystic ovary syndrome? Metabolism 2015. 64 1564–1573. (10.1016/j.metabol.2015.08.010)
    1. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, et al Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Human Reproduction Update 2011. 17 741–760. (10.1093/humupd/dmr025)
    1. Barber TM, Vojtechova P, Franks S. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome. Hormone Molecular Biology and Clinical Investigation 2013. 15 91–103. (10.1515/hmbci-2013-0014)
    1. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. & PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006. 91 48–53. (10.1210/jc.2005-1329)
    1. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome – a hypothesis. Journal of Endocrinology 2002. 174 1–5. (10.1677/joe.0.1740001)
    1. Elbers JMH, Asscheman H, Seidell JC, Megens JAJ, Gooren LJG. Long-term testosterone administration increases visceral fat in female to male transsexuals. Journal of Clinical Endocrinology and Metabolism 1997. 82 2044–2047. (10.1210/jcem.82.7.4078)
    1. Jones H, Sprung VS, Pugh CJA, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, et al Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2012. 97 3709–3716. (10.1210/jc.2012-1382)
    1. Barber TM, Wass JAH, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clinical Endocrinology 2007. 66 513–517. (10.1111/j.1365-2265.2007.02764.x)
    1. Broekmans F, Knauff E, Valkenburg O, Laven J, Eijkemans M, Fauser B. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 2006. 113 1210–1217. (10.1111/j.1471-0528.2006.01008.x)
    1. O’Reilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, Stewart PM, Tomlinson JW, Arlt W. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. Journal of Clinical Endocrinology and Metabolism 2014. 99 1027–1036. (10.1210/jc.2013-3399)
    1. Meun C, Franco OH, Dhana K, Jaspers L, Muka T, Louwers Y, Ikram MA, Fauser BCJM, Kavousi M, Laven JSE. High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: the Rotterdam Study. Journal of Clinical Endocrinology and Metabolism 2018. 103 1622–1630. (10.1210/jc.2017-02421)
    1. Ganie M, Zargar M, Zargar MA, Bhat D, Mir MM, Jan A, Shah ZA, Jan V, Rasool R, Naqati A. Prevalence of metabolic syndrome in the family members of women with polycystic ovary syndrome from North India. Indian Journal of Endocrinology and Metabolism 2014. 18 364 (10.4103/2230-8210.131186)
    1. Sáez ME, González-Sánchez JL, Ramírez-Lorca R, Martínez-Larrad MT, Zabena C, González A, Morón FJ, Ruiz A, Serrano-Ríos M. The CAPN10 gene is associated with insulin resistance phenotypes in the spanish population. PLoS ONE 2008. 3 e2953 (10.1371/journal.pone.0002953)
    1. Baldani D, Skrgatic L, Cerne J, Oguic S, Gersak B, Gersak K. Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome. Molecular Medicine Reports 2014. 11 3941–3947. (10.3892/mmr.2014.3117)
    1. Zhang R, Song Q, Liu H, Bai H, Zhang Y, Liu Q, Guan L, Fan P. Effect of the R92H and A379V genotypes of platelet-activating factor acetylhydrolase on its enzyme activity, oxidative stress and metabolic profile in Chinese women with polycystic ovary syndrome. Lipids in Health and Disease 2017. 16 57 (10.1186/s12944-017-0448-z)
    1. Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Yilmaz C. The relationship of the interleukin-6 −174 G>C gene polymorphism with cardiovascular risk factors in Turkish polycystic ovary syndrome patients. International Journal of Immunogenetics 2009. 36 283–288. (10.1111/j.1744-313X.2009.00867.x)
    1. Cetinkalp S, Karadeniz M, Erdogan M, Zengi A, Cetintas V, Tetik A, Eroglu Z, Kosova B, Ozgen AG, Saygili F, et al Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey. Journal of Assisted Reproduction and Genetics 2009. 26 1–6. (10.1007/s10815-008-9280-8)
    1. Ozegowska K, Bogacz A, Bartkowiak-WIeczorek J, Seremak-Mrozikiewicz A, Pawelczyk L. Is there association between the development of metabolic syndrome in polycystic ovary syndrome patients with the C677T metylenetetrahydrofolate reuctace gene polymorphism? Polish Gynaecology 2016. 87 246–253. (10.17772/gp/61751)
    1. Jones MR, Chua AK, Mengesha EA, Taylor KD, Chen YD, Li X, Krauss RM, Rotter JI, Legro RS. Metabolic and cardiovascular genes in polycystic ovary syndrome: a candidate-wide association study (CWAS). Steroids 2012. 77 317–322. (10.1016/j.steroids.2011.12.005)
    1. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001. 103 1410–1415. (10.1161/01.CIR.103.10.1410)
    1. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A, Michalis LK. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005. 90 5088–5095. (10.1210/jc.2005-0151)
    1. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arteriosclerosis, Thrombosis and Vascular Biology 2000. 20 2414–2421. (10.1161/01.ATV.20.11.2414)
    1. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Human Reproduction 2007. 22 3197–3203. (10.1093/humrep/dem324)
    1. Talbott EO, Zborowski J V, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004. 89 5454–5461. (10.1210/jc.2003-032237)
    1. Orio F, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004. 89 4588–4593. (10.1210/jc.2003-031867)
    1. Sprung VS, Atkinson G, Cuthbertson DJ, Pugh CJ, Aziz N, Green DJ, Cable NT, Jones H. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clinical Endocrinology 2013. 78 438–446. (10.1111/j.1365-2265.2012.04490.x)
    1. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2012. 18 112–126. (10.1093/humupd/dmr046)
    1. Hurliman A, Keller Brown J, Maille N, Mandala M, Casson P, Osol G. Hyperandrogenism and insulin resistance, not changes in body weight, mediate the development of endothelial dysfunction in a female rat model of polycystic ovary syndrome (PCOS). Endocrinology 2015. 156 4071–4080. (10.1210/en.2015-1159)
    1. Calderon-Margalit R, Siscovick D, Merkin SS, Wang E, Daviglus ML, Schreiner PJ, Sternfeld B, Williams OD, Lewis CE, Azziz R, et al Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the coronary artery risk development in young adults women’s study. Arteriosclerosis, Thrombosis and Vascular Biology 2014. 34 2688–2694. (10.1161/ATVBAHA.114.304136)
    1. Patel SS, Truong U, King M, Ferland A, Moreau KL, Dorosz J, Hokanson JE, Wang H, Kinney GL, Maahs DM, et al Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers. Vascular Medicine 2017. 22 85–95. (10.1177/1358863X16682107)
    1. Tripathy P, Sahu A, Sahu M, Nagy A. Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology 2017. 217 18–22. (10.1016/j.ejogrb.2017.08.011)
    1. Ketel IJ, Stehouwer CD, Henry RM, Serne EH, Hompes P, Homburg R, Smulders YM, Lambalk CB.Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity – but not a PCOS-associated phenomenon. Journal of Clinical Endocrinology and Metabolism 2010. 95 4566–4575. (10.1210/jc.2010-0868)
    1. Macut D, Bačević M, Božić-Antić I, Bjekić-Macut J, Čivčić M, Erceg S, Vojnović Milutinović D, Stanojlović O, Andrić Z, Kastratović-Kotlica B, et al Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. International Journal of Endocrinology 2015. 2015 1–9. (10.1155/2015/812610)
    1. Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovascular Diabetology 2018. 17 37 (10.1186/s12933-018-0680-5)
    1. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Annals of Internal Medicine 1997. 126 32–35. (10.7326/0003-4819-126-1-199701010-00005)
    1. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003. 88 2562–2568. (10.1210/jc.2003-030334)
    1. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 2002. 87 2013–2017. (10.1210/jcem.87.5.8471)
    1. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Human Fertility 2000. 3 101–105. (10.1080/1464727002000198781)
    1. Wang ET, Cirillo PM, Vittinghoff E, Bibbins-Domingo K, Cohn BA, Cedars MI. Menstrual irregularity and cardiovascular mortality. Journal of Clinical Endocrinology and Metabolism 2011. 96 E114–E118. (10.1210/jc.2010-1709)
    1. Ding T, Hardiman PJ, Petersen I, Wang F-F, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget 2015. 8 96351–96358. (10.18632/oncotarget.19180)
    1. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. Journal of Clinical Endocrinology and Metabolism 2011. 96 3794–3803. (10.1210/jc.2011-1677)
    1. de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Human Reproduction Update 2011. 17 495–500. (10.1093/humupd/dmr001)
    1. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010. 95 2038–2049. (10.1210/jc.2009-2724)
    1. Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility 2012. 97 28–38. (10.1016/j.fertnstert.2011.09.024)
    1. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, et al The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European Journal of Endocrinology 2014. 171 P1–P29. (10.1530/EJE-14-0253)
    1. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. & Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2013. 98 4565–4592. (10.1210/jc.2013-2350)
    1. Pullman D, Zarzeczny A, Picard A. Media, politics and science policy: MS and evidence from the CCSVI Trenches. BMC Medical Ethics 2013. 14 6 (10.1186/1472-6939-14-6)
    1. Fishman PA. Impact of broadened coverage of smoking cessation treatments on cardiovascular disease. Current Cardiovascular Risk Reports 2012. 6 542–548. (10.1007/s12170-012-0275-8)
    1. Barry CL, Martin A, Busch SH. ADHD medication use following FDA risk warnings. Journal of Mental Health Policy and Economics 2012. 15 119–125.
    1. Sanchez N, Jones H. ‘Less than a wife’: a study of polycystic ovary syndrome content in teen and women’s digital magazines. Journal of Medical Internet Research 2016. 18 e89 (10.2196/jmir.5417)
    1. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility 2009. 92 1966–1982. (10.1016/j.fertnstert.2008.09.018)
    1. Mehrabani HH, Salehpour S, Amiri Z, Farahani SJ, Meyer BJ, Tahbaz F. Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study. Journal of the American College of Nutrition 2012. 31 117–125. (10.1080/07315724.2012.10720017)
    1. Salama A, Amine E, Salem HE, Abd El Fattah N. Anti-inflammatory dietary combo in overweight and obese women with polycystic ovary syndrome. North American Journal of Medicine and Science 2015. 7 310 (10.4103/1947-2714.161246)
    1. Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clinical Endocrinology 2012. 77 343–350. (10.1111/j.1365-2265.2012.04434.x)
    1. Rahimi-Ardabili H, Gargari BP, Farzadi L. Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. Journal of Endocrinological Investigation 2013. 36 28–32. (10.3275/8303)
    1. He C, Lin Z, Robb S, Ezeamama A. Serum vitamin D levels and polycystic ovary syndrome: a systematic review and meta-analysis. Nutrients 2015. 7 4555–4577. (10.3390/nu7064555)
    1. Krul-Poel YHM, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, Simsek S. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. European Journal of Endocrinology 2013. 169 853–865. (10.1530/EJE-13-0617)
    1. Sprung VS, Cuthbertson DJ, Pugh CJ, Aziz N, Kemp GJ, Daousi C, Green DJ, Cable NT, Jones H. Exercise training in polycystic ovarian syndrome enhances flow-mediated dilation in the absence of changes in fatness. Medicine and Science in Sports and Exercise 2013. 45 2234–2242. (10.1249/MSS.0b013e31829ba9a1)
    1. Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, Phung OJ, Wang A, Hoeger K, Pasquali R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 2013. 98 4655–4663. (10.1210/jc.2013-2385)
    1. Thomson RL, Brinkworth GD, Noakes M, Clifton PM, Norman RJ, Buckley JD. The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. Human Reproduction 2012. 27 2169–2176. (10.1093/humrep/des138)
    1. Dantas WS, Murai IH, Perandini LA, Azevedo H, Moreira-Filho CA, Camara NO, Roschel H, Gualano B. Acute exercise elicits differential expression of insulin resistance genes in the skeletal muscle of patients with polycystic ovary syndrome. Clinical Endocrinology 2017. 86 688–697. (10.1111/cen.13307)
    1. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine 1996. 335 617–623. (10.1056/NEJM199608293350902)
    1. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Annals of Internal Medicine 2002. 137 25–33. (10.7326/0003-4819-137-1-200207020-00009)
    1. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. Journal of Clinical Endocrinology and Metabolism 2001. 86 4666–4673. (10.1210/jcem.86.10.7904)
    1. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J, Mavrikakis M. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology 2005. 152 749–756. (10.1530/eje.1.01910)
    1. Yang PK, Hsu CY, Chen MJ, Lai MY, Li ZR, Chen CH, Chen SU, Ho HN. The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2018. 103 890–899. (10.1210/jc.2017-01739)
    1. Patel R, Shah G. Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion 2017. 33 1545–1557. (10.1080/03007995.2017.1279597)
    1. Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reproduction Update 2016. 22 408–409. (10.1093/humupd/dmv063)
    1. Ibáñez L, Díaz M, Sebastiani G, Marcos MV, López-Bermejo A, de Zegher F. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity. Journal of Clinical Endocrinology and Metabolism 2013. 98 E902–E907. (10.1210/jc.2013-1041)
    1. Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones 2015. 14 81–90. (10.14310/horm.2002.1576)
    1. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovascular Therapeutics 2012. 30 e146–e155. (10.1111/j.1755-5922.2010.00256.x)
    1. Vyas AK, Yang K-C, Woo D, Tzekov A, Kovacs A, Jay PY, Hruz PW. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE 2011. 6 e17178 (10.1371/journal.pone.0017178)
    1. Hoang V, Bi J, Mohankumar SM, Vyas AK. Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS ONE 2015. 10 e0126119 (10.1371/journal.pone.0126119)
    1. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008. 93 2670–2678. (10.1210/jc.2008-0115)
    1. Jensterle M, Goricar K, Janez A. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. Endocrine Research 2017. 42 261–268. (10.1080/07435800.2017.1294602)
    1. Bajuk Studen K, Šebeštjen M, Pfeifer M, Preželj J. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. European Journal of Endocrinology 2011. 164 389–395. (10.1530/EJE-10-0709)
    1. Malik SM, Traub ML. Defining the role of bariatric surgery in polycystic ovarian syndrome patients. World Journal of Diabetes 2012. 3 71 (10.4239/wjd.v3.i4.71)
    1. Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of ‘obesity-associated gonadal dysfunction’ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Human Reproduction Update 2017. 23 390–408. (10.1093/humupd/dmx012)

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj